Início › Leucemia Bifenotípica Aguda › Iowa
Ensaios clínicos de Leucemia Bifenotípica Aguda em Iowa
4 estudos para Leucemia Bifenotípica Aguda estão buscando participantes em locais em Iowa.
Cidades em Iowa
Texto oficial do estudo (Inglês)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Blank Children's Hospital, Des Moines
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
RecrutandoFase 1/2
30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.